Abstract
Innovation in pharmaceutical industry means to discover something new with therapeutic properties. It is a fundamental demand of organizations to achieve success in the market, as it represents a competitive advantage. In general, many factors stand in the way of innovating companies, universities and research institutes. When we talk about the public sector, there are many challenges. This article aims at presenting some of the main obstacles faced by the Brazilian public pharmaceutical institutions negatively contributing to innovation: difficulties related to infrastructure; funding and purchasing processes; discrepancies between the pharmaceutical industry institutional goals and the Ministry of Health’s demands; the need to introduce quality requirements in early stages of research; and the focus on technology transfer processes as the only source for innovation. Challenges are many, but with mood and motivation, both by the involved professionals and by the Brazilian government - which must show willingness to seek strategies to modify the current scenario -, it will be possible to reach an innovation culture in Brazil.
Highlights
Innovation in pharmaceutical industry means to discover something new with therapeutic properties
A discrepância entre as colocações demonstra a dificuldade do país em atravessar a larga ponte que ainda separa a academia do setor produtivo[3]
Para que haja menos entraves na compra e aquisição de equipamentos, por parte das instituições públicas farmacêuticas, faz-se necessário uma grande reestruturação em toda a rede de laboratórios oficiais, assim como alterações na Lei no 8666/1993, de forma a facilitar a modernização destes laboratórios e de modo a tornar o ambiente mais propício a novas ideias e novos processos, pois pode-se observar que, mesmo com as alterações já realizadas na referida lei, ainda existem entraves importantes
Summary
Innovation in pharmaceutical industry means to discover something new with therapeutic properties. Quando falamos do setor público, especificamente, encontramos desafios diversos, como: longo tempo para a aquisição de materiais e de novos equipamentos, em virtude dos lentos processos de compra; infraestrutura antiga e não condizente com o que está sendo desenvolvido e com o número de pessoas envolvidas; objetivos institucionais incoerentes em relação às demandas do Ministério da Saúde (MS); gestão deficiente; a falta de cumprimento de algumas normas específicas nas etapas de P&D; e, finalmente, esforços ainda inconsistentes no que se refere à inovação a partir de P&D.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
